Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Myelodysplastic Syndromes 2Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 21fludarabine 20fludarabine phosphate 17Tacrolimus 12thymoglobulin 11Whole-Body Irradiation 11Busulfan 10Azacitidine 10Mycophenolic Acid 9Methotrexate 9Thiotepa 8Melphalan 8Antilymphocyte Serum 8venetoclax 7AP 1903 reagent 7Rituximab 6Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5merphos 4aldesleukin 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Interleukin-2 4Dexamethasone 4enasidenib 3Tretinoin 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Darbepoetin alfa × Myeloid × Clear all
NCT00230321 2013-02-04

A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)

Stanford University

Phase 1/2 Completed
21 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡